Seeking Alpha

JPMorgan defends its Overweight rating of United Therapeutics (UTHR) despite the failure of the...

JPMorgan defends its Overweight rating of United Therapeutics (UTHR) despite the failure of the phase III FREEDOM-C trial to meet its primary goal. Deutsche drops to Hold with a $70 target. Barclays defends a Buy and a $137 target. Shares -33% to $60.25.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs